ldn

Low-Dose Naltrexone for Severe Fibromyalgia Syndrome: A Report of a Case With Two-Year Follow-Up Ulrich Moser [Line breaks added] Abstract Fibromyalgia syndrome (FMS) is characterized by diffuse musculoskeletal pain associated with daytime fatigue, sleep disturbance, cognitive deficits, and...

Abstract Low-dose naltrexone (LDN) has demonstrated mixed efficacy in treating fibromyalgia. This systematic review and meta-analysis aimed to evaluate the efficacy of LDN for fibromyalgia. We systematically searched electronic databases and gray literature from inception to May 2024. Included...

How I treat my patients with Myalgic Encephalomyelitis, Chronic Fatigue Syndrome (ME/CVS), fibromyalgia or “long COVID” Frank Comhaire Abstract Common to Myalgic encephalomyelitis, chronic fatigue syndrome and so-called long Covid is the panoply of complaints, with Post Exertional Malaise...

Low-Dose Naltrexone restored TRPM3 ion channel function in Natural Killer cells from long COVID patients Etianne Martini Sasso, Natalie Eaton-Fitch, Peter Kenneth Smith, Muraki Katsuhiko, Sonya Marshall-Gradisnik [Line breaks] Abstract Long COVID is a multisystemic condition that includes...

I am highly skeptical of this, I was already in disbelief at the number of illnesses claimed to be treated by LDN, but now cancer? Seems way too good to be true. PS: Bloor Pain Specialists has an unfortunate acronym.

Hi, I am curious as to whether anyone has some developed hypotheses as to the mechanism of 'low-dose' Naltrexone? Much of the discourse about Naltrexone is dominated by discussion of it being a competitive inhibitor of the function of of mu-opioid receptors. But it is known that at lower...

Abstract Introduction: Fibromyalgia (FM) is a chronic fluctuating, nociplastic pain condition. Naltrexone is a µ-opioid-receptor antagonist; preliminary studies have indicated a pain-relieving effect of low-dose naltrexone (LDN) in patients with FM. The impetus for studying LDN is the...

Full title: Potential pathophysiological role of the ion channel TRPM3 in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and the therapeutic effect of low-dose naltrexone Abstract Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) is a debilitating disease with a broad...

Discussion moved from the OMF news thread. Trial details - mestinon and/or LDN https://www.omf.ngo/lift-trial/

Highlights The off-label use of low-dose naltrexone (LDN) is a potential drug intervention for the management of post-COVID conditions. LDN has anti-inflammatory and immunomodulatory properties which may benefit those with PASC where persistent inflammation is the causative pathway. LDN...

This much cited (over 1600 citations) study from 1978 claims to have proven the placebo effect is real. https://pubmed.ncbi.nlm.nih.gov/80579/

Abstract: Chronic Fatigue and Immune Dysfunction Syndrome (CFIDS) is considered to be a multidimensional illness whose etiology is unknown. However, reports from Chernobyl, as well as those from the United States, have revealed an association between radiation exposure and the development of...

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5489802/ Open access Abstract Fibromyalgia (FM) is a complex, multi-symptom condition that predominantly affects women. The majority of those affected are unlikely to gain significant symptomatic control from the few treatments that are approved for...

https://link.springer.com/article/10.1007/s10067-014-2517-2 Open access Abstract Low-dose naltrexone (LDN) has been demonstrated to reduce symptom severity in conditions such as fibromyalgia, Crohn’s disease, multiple sclerosis, and complex regional pain syndrome. We review the evidence that...

The UK government working party on research strategy for ME has been discussing the value of setting up trials for drug repurposing. LDN is a contender. I would be interested in the range of experience - positive or negative - amongst members.

The drug has been used with some success to treat a similar complex, post-infectious syndrome marked by cognitive deficits and overwhelming fatigue called myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Drawing on its use in ME/CFS and a handful of long COVID pilot studies, there...

Highlights Low dose naltrexone (LDN) is safe to use in patients with long covid (LC). In patients with LC for a median 11 months, LDN reduced symptoms at 2 months. In this cohort, LDN also improved well-being in 6 of 7 parameters at 2 months. Abstract Background Up to 37.7% of patients...

Clinical trial registration. There is a growing number of individuals who do not recover to previous levels of health and function following an acute infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but rather develop what has been referred to as 'Long-COVID'...

Abstract Background Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a serious disorder of unknown aetiology. While the pathomechanism of ME/CFS remains elusive, reduced natural killer (NK) cell cytotoxic function is a consistent immunological feature. NK cell effector functions...

Full title: Study protocol for a randomised, double-blinded, placebo-controlled phase III trial examining the add-on efficacy, cost-utility and neurobiological effects of low-dose naltrexone (LDN) in patients with fibromyalgia (INNOVA study). Abstract Introduction There is evidence that...